Romosozumab or alendronate for fracture prevention in East Asian patients: a subanalysis of the phase III, randomized ARCH study

por Lau, E. M. C., Dinavahi, R., Woo, Y. C., Wu, C.-H., Guan, J., Maddox, J., Tolman, C., Yang, W., Shin, C. S.
Publicado 2020